Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y]
- BOND RX™ Validated
- RabMAb
- Recombinant
- What is this?
5
(6 Reviews)
|
(45 Publications)
Rabbit Recombinant Monoclonal p27 KIP 1 phospho S10 antibody. Suitable for WB, IP, Dot, IHC-P and reacts with Mouse, Rat, Human, Monkey, Synthetic peptide samples. Cited in 45 publications.
View Alternative Names
KIP1, p27, CDKN1B, Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor p27, p27Kip1
- IHC-P
Lab
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (AB62364)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human colon cancer tissue sections labeling p27 KIP 1 with Purified ab62364 at 1 : 100 dilution (4.19 µg/ml). Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0). Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- IP
Unknown
Immunoprecipitation - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (AB62364)
Purified ab62364 at 1/50 dilution (2μg) immunoprecipitating p27 KIP 1 in MCF7 whole cell lysate.
Lane 1 (input) : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab62364 + MCF7 whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab62364 in MCF7 whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 27 kDa
All lanes:
Immunoprecipitation - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (ab62364)
Predicted band size: 22 kDa
false
- WB
Unknown
Western blot - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (AB62364)
Blocking buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (ab62364) at 1/1000 dilution
Lane 1:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 15 µg
Lane 2:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate, membrane treated with Alkaline Phosphatase for 1 hour at 15 µg
Lane 3:
NIH/3T3 (Mouse embryonic fibroblast) whole cell lysate at 15 µg
Lane 4:
NIH/3T3 (Mouse embryonic fibroblast) whole cell lysate, membrane treated with Alkaline Phosphatase for 1 hour at 15 µg
Lane 5:
C6 (Rat glial tumor glial cell) whole cell lysate at 15 µg
Lane 6:
C6 (Rat glial tumor glial cell) whole cell lysate, membrane treated with Alkaline Phosphatase for 1 hour at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 22 kDa
Observed band size: 27 kDa
false
- Dot
Unknown
Dot Blot - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (AB62364)
Dot blot analysis of p27 KIP 1 (pS10) phospho peptide (Lane 1) and p27 KIP 1 non-phospho peptide (Lane 2) using ab62364 at 1/1000 dilution followed by Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100000 dilution.
Blocking and Diluting buffer and concentration : 5% NFDM /TBST.
Exposure time : 3 minutes.
- WB
CiteAb
Western blot - Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] (AB62364)
p27 KIP 1 (phospho S10) western blot using anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] ab62364. Publication image and figure legend from van der Laden, J., Soppa, U., et al., 2015, Cell Commun Signal, PubMed 25630557.
ab62364 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab62364 please see the product overview.
Maximal activity of HIPKs depends on the activation loop tyrosine. Wild type GFP-HIPK fusion proteins and the respective Tyr→Phe mutants were immunoprecipitated from HeLa cells and subjected to kinase assays with recombinant GST-p27Kip1(A), myelin basic protein (B) or DYRKtide (C). GFP served as background control. A, Phosphorylation of p27Kip1 at Ser10 was detected by immunoblot with a phosphorylation-specific antibody. For quantitative evaluation, pSer10 immunoreactivity was normalised to GFP immunoreactivity, which reflects the amount of kinase in the reaction. The blots illustrate a representative experiment, and the relative catalytic activities as determined from 3–4 assays are shown below the panels (means ± SD). One-sample t test : *, p < 0.05; **, p < 0.01. B and C, Phosphorylation of MBP and DYRKtide was measured in triplicate as incorporation of 32P. Background values from the GFP control samples were subtracted and activities were normalised to the amount of kinase in the reaction as determined by GFP immunoreactivity. Column diagrams illustrate catalytic activities relative to HIPK2 (WT). The results were replicated in independent experiments, except for a missing value of HIPK1.
false
Related conjugates and formulations (1)
-
Anti-p27 KIP 1 (phospho S10) antibody [EP233(2)Y] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The function of p27 KIP1 involves its role in controlling cell growth and division. It achieves this by becoming a part of larger protein complexes involving CDKs and cyclins. By directly interacting with these complexes p27 KIP1 modulates cell cycle progression therefore acting as a brake on cellular proliferation. The protein is important in maintaining proper cell cycle checkpoints and preventing uncontrolled cell growth which is essential for normal cellular functioning.
Pathways
The involvement of p27 KIP1 centers on cell cycle regulation and signaling pathways such as the PI3K/AKT pathway. Its interaction with CDKs and cyclins situates it within the core mechanisms that determine cell division timing. p27 KIP1 operates alongside other proteins like cyclin D and CDK4/6 fitting into the regulatory intricacies of these pathways. Proper functioning of these pathways ensures cellular homeostasis and prevents the development of oncogenic processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (45)
Recent publications for all applications. Explore the full list and refine your search
Signal transduction and targeted therapy 10:15 PubMed39828766
2025
Applications
Unspecified application
Species
Unspecified reactive species
Histology and histopathology 40:73-87 PubMed38818655
2024
Applications
Unspecified application
Species
Unspecified reactive species
Theranostics 14:1371-1389 PubMed38389850
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 24: PubMed38138967
2023
Applications
Unspecified application
Species
Unspecified reactive species
Experimental & molecular medicine 54:2022-2035 PubMed36424455
2022
Applications
Unspecified application
Species
Unspecified reactive species
Regenerative therapy 21:560-573 PubMed36475023
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular and molecular medicine 26:2981-2994 PubMed35429093
2022
Applications
Unspecified application
Species
Unspecified reactive species
Computational and mathematical methods in medicine 2022:2329576 PubMed35082911
2022
Applications
Unspecified application
Species
Unspecified reactive species
BioFactors (Oxford, England) 48:135-147 PubMed34856026
2021
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 12:4671 PubMed34344863
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com